RECURSION PHARMACEUTICALS, INC. Interest Expense
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Interest Expense of $20.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-09
- RECURSION PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $20.00K, a 5.26% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-12-31 was $26.00K, a 100.00% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $25.00K, a 92.31% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-06-30 was $26.00K, a 85.71% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $97.00K, a 76.36% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $55.00K, a 98.14% decline from fiscal 2021.
- RECURSION PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $2.95M, a 117.06% increase from fiscal 2020.
- RECURSION PHARMACEUTICALS, INC. interest expense for fiscal 2020 was $1.36M, a 114.17% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $20.00K 10-Q · filed 2024-05-09 | $46.00K derived: sum of 2 quarters · filed 2024-05-09 | $71.00K derived: sum of 3 quarters · filed 2024-05-09 | $97.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $51.00K derived: sum of 2 quarters · filed 2024-02-29 | $77.00K derived: sum of 3 quarters · filed 2024-02-29 | $97.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | $25.00K 10-Q · filed 2023-11-09 | $51.00K derived: sum of 2 quarters · filed 2023-11-09 | $71.00K 10-Q · filed 2023-11-09 | $83.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $26.00K 10-Q · filed 2023-08-08 | $45.00K 10-Q · filed 2023-08-08 | $58.00K derived: sum of 3 quarters · filed 2024-05-09 | $71.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $19.00K 10-Q · filed 2024-05-09 | $32.00K derived: sum of 2 quarters · filed 2024-05-09 | $45.00K derived: sum of 3 quarters · filed 2024-05-09 | $59.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $26.00K derived: sum of 2 quarters · filed 2024-02-29 | $40.00K derived: sum of 3 quarters · filed 2024-02-29 | $55.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $13.00K 10-Q · filed 2023-11-09 | $27.00K derived: sum of 2 quarters · filed 2023-11-09 | $42.00K 10-Q · filed 2023-11-09 | $22.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $14.00K 10-Q · filed 2023-08-08 | $28.00K 10-Q · filed 2023-08-08 | $9.00K derived: sum of 3 quarters · filed 2024-02-29 | $229.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $14.00K 10-Q · filed 2023-05-08 | -$5.00K derived: sum of 2 quarters · filed 2024-02-29 | $215.00K derived: sum of 3 quarters · filed 2024-02-29 | $2.72M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $201.00K derived: sum of 2 quarters · filed 2024-02-29 | $2.70M derived: sum of 3 quarters · filed 2024-02-29 | $2.95M 10-K · filed 2024-02-29 |
| 2021-09-30 | $220.00K 10-Q · filed 2022-11-08 | $2.72M derived: sum of 2 quarters · filed 2022-11-08 | $2.97M 10-Q · filed 2022-11-08 | $3.20M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.50M 10-Q · filed 2022-08-09 | $2.75M 10-Q · filed 2022-08-09 | $2.98M derived: sum of 3 quarters · filed 2023-02-27 | $3.38M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $249.00K 10-Q · filed 2022-05-10 | $480.00K derived: sum of 2 quarters · filed 2023-02-27 | $881.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.31M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $632.00K derived: sum of 2 quarters · filed 2023-02-27 | $1.06M derived: sum of 3 quarters · filed 2023-02-27 | $1.36M 10-K · filed 2023-02-27 |
| 2020-09-30 | $401.00K 10-Q · filed 2021-11-10 | $827.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.13M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $426.00K 10-Q · filed 2021-08-13 | $727.00K 10-Q · filed 2021-08-13 | ||
| 2019-12-31 | $635.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |